Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Non-cash Items (2018 - 2025)

Cue Biopharma (CUE) has disclosed Non-cash Items for 8 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 42.63% to $7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, up 42.63% year-over-year, with the annual reading at $7.3 million for FY2025, 42.63% up from the prior year.
  • Non-cash Items hit $7.3 million in Q4 2025 for Cue Biopharma, up from $7.2 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $7.3 million in Q4 2025 to a low of $3.1 million in Q1 2021.
  • Historically, Non-cash Items has averaged $4.8 million across 5 years, with a median of $4.4 million in 2022.
  • Biggest five-year swings in Non-cash Items: rose 0.18% in 2023 and later soared 42.63% in 2025.
  • Year by year, Non-cash Items stood at $3.6 million in 2021, then increased by 23.57% to $4.4 million in 2022, then increased by 4.53% to $4.6 million in 2023, then rose by 11.97% to $5.1 million in 2024, then skyrocketed by 42.63% to $7.3 million in 2025.
  • Business Quant data shows Non-cash Items for CUE at $7.3 million in Q4 2025, $7.2 million in Q3 2025, and $6.3 million in Q2 2025.